The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
Samsung hit with $191.4 million US jury verdict in OLED patent trial
By Blake Brittain (Reuters) -Samsung Electronics owes patent owner Pictiva Displays $191.4 million in damages for infringing two U.S. patents covering…
Nvidia’s strong forecast calms AI bubble jitters – for now
By Arsheeya Bajwa and Stephen Nellis (Reuters) -Nvidia forecast quarterly revenue well above Wall Street estimates on Wednesday and CEO…
Chevron Reveals $16B Of 2024 Capex Budget
Upstream spending in 2024 is expected to be about $14 billion. Downstream capex is expected to be roughly $1.5 billion, with 80 percent allocated to…